MilliporeSigma Launches Neutral Lipid Ahead of Schedule to Meet COVID-19 Demand

BioPharm International Editors

MilliporeSigma has launched SAFC, a high-purity synthetic cholesterol product, nine months ahead of schedule to meet the lipid demands for COVID-19 messenger RNA therapeutics.

MilliporeSigma announced on May 26, 2021 that it has launched SAFC, a high-purity synthetic cholesterol product, nine months ahead of schedule to meet the lipid demands for COVID-19 messenger RNA therapeutics.

The lipid, which is used in commercially marketed products, is more than 99% pure, provides high batch-to-batch consistency, and is scalable under commercial good manufacturing practices, according to a company press release.

“Tapping into two decades’ experience of developing and manufacturing high-quality lipids, we designed a proprietary process to bring our new SAFC synthetic cholesterol product to market nearly a year early,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma, in the press release. “With the introduction of our new SAFC synthetic cholesterol product, we have increased our capacity by 50 times, helping biomanufacturers bring lifesaving therapies to patients faster.”

Source: MilliporeSigma